Wegovy tablets are a once-daily semaglutide pill for weight management
Wegovy tablets contain semaglutide, the same medicine as the Wegovy injection, in a daily tablet that the FDA approved in December 2025. They are labeled for adults with obesity, or overweight plus a weight-related condition, alongside diet and activity. The pill has strict timing rules, real side effects, and results that differ a lot from person to person.
Information current as of November 10, 2026. Educational only. Confirm everything here with your own clinician before starting, stopping or changing any medication.
At a glance
Drug class
Semaglutide, a GLP-1 receptor agonist, made by Novo Nordisk. Prescription only.
How it is taken
One tablet each morning on an empty stomach with up to 4 ounces of plain water. Then wait at least 30 minutes before food, drinks or other pills.
Approval status
FDA-approved December 22, 2025, as a new dosage form of Wegovy, for weight reduction and maintenance.
Who it is for
Adults with obesity, or overweight plus a weight-related condition. Not studied for weight loss in type 2 diabetes.
Main cautions
Boxed warning for thyroid C-cell tumors. Stomach side effects are common. Not for use in pregnancy.
Who sells it
Novo Nordisk makes it and sets its own prices and sales channels. Summit does not dispense or sell it.
What it is
What Wegovy tablets are and how they work
Wegovy tablets contain semaglutide, a medicine that copies a gut hormone called GLP-1. The hormone slows how quickly the stomach empties and acts on appetite centers in the brain. Most people feel full sooner and think about food less.
The tablet pairs semaglutide with an absorption helper called SNAC, yet the label estimates only 1% to 2% of each dose reaches the bloodstream. That is why the dose is 25 mg and why the morning routine matters.
The FDA approved Wegovy tablets on December 22, 2025 (NDA 218316, Novo Nordisk). The label gives two uses, each with a reduced-calorie diet and more activity: reducing excess body weight and keeping it down long term in adults with obesity, or overweight plus a related condition; and lowering the risk of cardiovascular death, heart attack and stroke in adults who already have cardiovascular disease and obesity or overweight.
Fit
Who it is for and who it is not for
- The main tablet trial enrolled adults with a BMI of 30 or higher, or 27 or higher with a related condition such as high blood pressure.
- Adults with type 2 diabetes were left out. In that group the label notes the tablet’s average blood levels ran lower than the injection’s.
- Safety and effectiveness are not established under age 18.
Do not use Wegovy tablets if
- You or a family member has had medullary thyroid carcinoma, or you have a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- You have had a serious allergic reaction to semaglutide or to anything in the tablet or the injection.
- You are pregnant. Stop when pregnancy is recognized, and at least 2 months before a planned one.
- You are breastfeeding. SNAC reaches breast milk and its effect on a baby is unknown.
Taking it
How the tablets are taken
The tablet only works if the routine is followed. Per the label:
- Take one tablet in the morning on an empty stomach.
- Swallow it whole with up to 4 ounces of plain water. No coffee, juice or other liquid. Do not split, crush, chew or dissolve it.
- Wait at least 30 minutes before eating, drinking anything or taking other pills.
- Take no more than one tablet a day.
The dose steps
Treatment starts low and steps up every 30 days: 1.5 mg on days 1 to 30, 4 mg on days 31 to 60, 9 mg on days 61 to 90, then 25 mg from day 91 on. If a dose is missed, skip it and take the next one the following day.
Someone on the 2.4 mg Wegovy injection may switch to the 25 mg tablet one week after the last injection. This describes the label; your own schedule belongs to your prescriber.
Evidence
What the trials showed
OASIS 4: the tablet’s weight trial
OASIS 4 (Wharton and colleagues, New England Journal of Medicine, 2025) enrolled 307 adults without diabetes at 22 sites in four countries. Two thirds received 25 mg oral semaglutide and one third placebo, with lifestyle support for both. At week 64 the average change in body weight was -13.6% with the tablet and -2.2% with placebo, a difference of 11.4 percentage points. Novo Nordisk funded the trial.
The label reports the same study as Study 7. A loss of 5% or more occurred in 76.3% on the tablet and 31.3% on placebo, and 10% or more in 59.8% and 14.4%. Individual results vary.
The heart indication comes from an injection trial
The label’s cardiovascular evidence comes from SELECT (New England Journal of Medicine, 2023), a trial of the weekly injection. The tablet’s own trial measured weight, not heart attacks or strokes.
Pill and shot results are not directly comparable
The trials enrolled different people, ran for different lengths of time and used different methods. No trial cited here compared the tablet with the injection head to head. For the weekly options Summit prescribes, see compounded semaglutide and our injection-versus-pill guide.
Safety
Side effects and serious warnings
Boxed warning: thyroid C-cell tumors
Semaglutide caused thyroid C-cell tumors in rodents. Whether it does so in people has not been determined. Tell your prescriber right away about a lump in the neck, trouble swallowing, shortness of breath or hoarseness that does not go away.
Stomach effects are the main issue. Nausea, vomiting, diarrhea and constipation are common. In OASIS 4, stomach-related adverse events occurred in 74.0% on the tablet and 42.2% on placebo. In the label’s tablet safety data, 6.9% stopped because of side effects versus 5.9% on placebo. See semaglutide side effects and managing nausea.
Skin sensations. 5% on the tablet and none on placebo reported dysesthesia: tingling, burning or sensitive skin. See our dysesthesia explainer.
Other label warnings: pancreatitis; gallbladder disease (gallstones in 2.5% versus 1% on placebo); low blood sugar with insulin or a sulfonylurea; kidney injury from dehydration; allergic reactions; worsening diabetic retinopathy; a small rise in resting heart rate; and food or liquid entering the lungs during anesthesia.
Interactions
Other medicines and what is monitored
- Every other pill. The tablet must be taken alone, so other morning pills move to 30 minutes later or beyond.
- Levothyroxine. Exposure rose 33% with the tablet in an interaction study, so thyroid levels may need rechecking.
- Insulin and sulfonylureas. Low blood sugar risk rises, and the dose of either may need to come down.
Stopping
What happens if you stop
This page does not cite a study of stopping the tablet. Obesity is chronic, and appetite signals tend to return when a GLP-1 medicine ends. Plan the end before the start. See stopping without regaining weight and maintenance after goal weight.
Choosing
A daily pill, a weekly shot, or neither
A pill removes the needle. The cost is a rule every morning. If your mornings are unpredictable because of shift work, young children or an early commute, a weekly injection with no meal rule may fit better. For some people neither is right.
The free GLP-1 quiz lays out the questions. If you are on Medicare, try the Medicare coverage navigator. Our guide to compounded and brand-name medications explains the difference. For another daily pill, see Foundayo.
Summit’s role
What Summit does and does not do with Wegovy tablets
Summit does not dispense or sell Wegovy tablets or any other brand-name product. Novo Nordisk makes them and sets its own prices and sales channels. Summit’s own programs are on the pricing page.
What Summit does prescribe, after a physician evaluation, is compounded semaglutide or compounded tirzepatide, made for you by an independent state-licensed pharmacy. Compounded medications are not FDA-approved, and the FDA has not evaluated their safety, effectiveness or quality. They are not the brand-name product.
Whether Wegovy tablets fit you is a decision Dr. Miranda makes after your history and labs. He can talk through whether a daily pill, a weekly compounded injection, or neither makes sense for you. Applying is not a prescription.
Common questions
Questions people ask
Can I take Wegovy tablets with coffee?
No. Take the tablet on an empty stomach with up to 4 ounces of plain water and no other liquid, then wait at least 30 minutes before food, drinks or other pills.
What if I miss a dose?
Skip the missed dose and take the next one the following day. Do not take two tablets in one day.
Can I use it while pregnant or breastfeeding?
No. The label says to stop when pregnancy is recognized, to stop at least 2 months before a planned pregnancy, and that breastfeeding is not recommended with the tablets.
Does Summit sell Wegovy tablets?
No. Summit does not dispense or sell brand-name products. Novo Nordisk sets the price and channels. Dr. Miranda can help you decide whether a pill, a compounded weekly injection, or neither fits.
Sources
Where this comes from
All retrieved November 10, 2026.
- Novo Nordisk. Wegovy (semaglutide) injection and tablets, prescribing information. DailyMed, label read November 10, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- FDA. Drugs@FDA: Wegovy tablets, NDA 218316 (approved December 22, 2025). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316
- Wharton S, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med 2025. PMID 40934115. https://doi.org/10.1056/NEJMoa2500969
- SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023. PMID 37952131. https://doi.org/10.1056/NEJMoa2307563
Confirm with your provider. This page is general education, not medical advice, and it does not diagnose or treat anything. Every medication carries risks and is not right for everyone. Medication is prescribed only after a physician evaluation determines it is appropriate for you. Individual results vary and no outcome is guaranteed. Information current as of November 10, 2026.
Next step
Talk it through with a physician first
Dr. Miranda reviews your history and labs, then decides whether a daily pill, a weekly compounded injection, or neither fits you.